Tóth E, Fork F T, Lindelöw K, Lindström E, Verbaan H, Veress B
Röntgendiagnostiska avdelningen, Universitetssjukhuset MAS.
Lakartidningen. 1998 Aug 26;95(35):3676-80.
The bisphosphonate, alendronate sodium (e.g. Fosamax), a bone resorption inhibitor used to treat osteoporosis, has occasionally been reported to cause severe oesophagitis. The characteristic endoscopy findings include oesophageal ulceration with discoloured exudate, a narrowed lumen and denuded, haemorrhagic mucosa. The oesophagitis heals on discontinuation of alendronate medication, and the institution of gastric acid suppression treatment. The article consists in discussion of such adverse reactions, illustrated by three case reports. As many of the patients selected for alendronate treatment are elderly and handicapped, to minimise the risk of serious side-effects it is important not only to give detailed instructions regarding medication, but also to ensure that they are properly understood. As a history of swallowing problems was a feature of all three cases reported, caution is recommended before treating such patients with alendronate sodium.
双膦酸盐类药物阿仑膦酸钠（如福善美）是一种用于治疗骨质疏松症的骨吸收抑制剂，偶尔有报道称其会导致严重食管炎。典型的内镜检查结果包括伴有变色渗出物的食管溃疡、管腔狭窄以及黏膜剥脱、出血。停用阿仑膦酸盐药物并进行胃酸抑制治疗后，食管炎可愈合。本文通过三例病例报告对这类不良反应进行了讨论。由于许多接受阿仑膦酸盐治疗的患者年老体弱，为将严重副作用的风险降至最低，不仅要详细说明用药方法，还要确保患者正确理解，这一点很重要。鉴于所报道的三例病例均有吞咽问题病史，建议在使用阿仑膦酸钠治疗此类患者时谨慎行事。
